MedWatch

Huge acquisition scores Novo Nordisk an FDA-ready treatment

Through acquiring Dicerna, Novo Nordisk is getting its hands on a drug candidate that is expected to be submitted for FDA approval during first quarter of 2022.

In around a year's time, Novo Nordisk may be able to enter a new market with an approved treatment under its belt, after its USD 3.3bn acquisition of Dicerna.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Extra data boosts Lundbeck's agitation case

Pharmaceutical firm Lundbeck has presented positive new data at a US conference as it seeks approval for its candidate Rexulti as a treatment for agitation in Alzheimer’s patients.

Further reading

Related articles

Latest news

See all jobs